Clovis Focuses on Rubraca Label Expansion, Competition Stiff

The commercial portfolio of Clovis consists of a single drug, Rubraca, which is approved as a maintenance treatment in recurrent ovarian cancer patients in second-line setting. The drug is also approved for treating BRCA mutated ovarian cancer in third or later-line setting. The company had in-licensed Rubraca from Pfizer PFE in 2011.